Background: The progression of emphysema and airfi ow limitation in chronic obstructive pulmonary disease (COPD) leads to static hyperinfi ation. However, few studies have been conducted so far regarding the prognostic value of static hyperinfi ation ...
Background: The progression of emphysema and airfi ow limitation in chronic obstructive pulmonary disease (COPD) leads to static hyperinfi ation. However, few studies have been conducted so far regarding the prognostic value of static hyperinfi ation marked by residual volume (RV)/ total lung capacity (TLC). Therefore we attempted to fi nd the independent factors related to static hyperinfi ation and to test the hypothesis that static hyperinfi ation is associated with the prognosis of COPD. Methods: We analyzed 380 COPD patients of our Korean Obstructive Lung Disease (KOLD) cohort who were recruited from 16 hospitals in Korea from June 2005 to April 2012. Hyperinfi ated COPD was defi ned as 40% or more of RV/ TLC. Results: Patients with hyperinfi ated COPD was older and male dominant, and had worse pulmonary function (represented by lower FEV1, FEV1/FVC, and FVC), higheremphysema index, and severer air-trapping, compared to non-hyperinfiated COPD group (p<0.05). Multiple logistic regression analysis demonstrated that age (OR = 1.071), FEV1 (OR = 0.923), FEV1/FVC (OR = 0.948), and emphysema index (OR = 1.036) were independently associated with severe static hyperinfiation ( RV/TLC =40%) (p<0.05). According to the severity of static hyperinfi ation, mean survival period was shorter (RV/TLC = 60% : 77.7 ± 4.6 months, 40 = RV/TLC <60 : 94.3 ± 1.9 months, RV/TLC < 40 % : 95.1 ± 1.8 months, p<0.05) and acute exacerbation was more frequent (p<0.05). Conclusions: Old age, emphysema index, FEV1, and FEV1/FVC were independent factors associated with hyperinfi ated COPD. The survival period was shorter according to the severity of static hyperinfi ation. This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for health and welfare (A102065).